Cytochrome P450 (P450) enzymes play important roles in the metabolism of endogenous and xenobiotic substrates in humans. CYP2C8 is an important member of the CYP2C subfamily, which metabolizes both endogenous compounds (i.e., arachidonic acids and retinoic acid) and xenobiotics (e.g., paclitaxel). Induction of P450 enzymes by drugs can result in tolerance as well as drug-drug interactions. CYP2C8 is the most strongly inducible member of the CYP2C subfamily in human hepatocytes, but the mechanism of induction by xenobiotics has not been delineated. To determine the mechanisms controlling the regulation of this important P450, we cloned the 5Ј-flanking region of CYP2C8 and investigated its transcriptional regulation by nuclear factors such as the pregnane X receptor (PXR), constitutive androstane receptor (CAR), glucocorticoid receptor (GR), and hepatic nuclear factor 4 (HNF4␣) that are known to be involved in the induction of other P450 enzymes using both cell lines and primary hepatocyte models. We initially identified a distal PXR/CAR-binding site in the CYP2C8 promoter that confers inducibility of CYP2C8 via the PXR agonist/ligand rifampicin and the CAR agonist/ligand
The CYP2C subfamily of cytochrome P450 enzymes is an important class of drug-metabolizing enzymes responsible for the metabolism of approximately 20% of all clinically prescribed therapeutics (Goldstein, 2001) . In humans, this subfamily is composed of four members-CYP2C8, CYP2C9, CYP2C18, and CYP2C19-that are localized within a single gene locus on chromosome 10. Significant progress has been made in elucidating the pharmacological and physiological functions of these enzymes in human liver; however, only recently have reports emerged describing the factors that influence their transcriptional regulation (Pascussi et al., 2000; Ferguson et al., 2002; Bort et al., 2004; Chen et al., 2004) . Of the four CYP2C isozymes, CYP2C9 and CYP2C8 proteins are expressed at the highest levels in human liver (Goldstein and de Morais, 1994; Inoue et al., 1994) , whereas CYP2C9 Ͼ CYP2C19 Ͼ CYP2C8 are expressed in small intestine (Lapple et al., 2003) . CYP2C8 expression has also been reported in kidney, lung, nasal mucosa, and heart (Klose et al., 1999; Ding and Kaminsky, 2003) .
Our laboratory has recently examined the regulation of CYP2C gene expression by clinically prescribed drugs such as phenobarbital, rifampicin, and dexamethasone (Ferguson et al., 2002; Chen et al., 2003 Chen et al., , 2004 . We have identified transcription factor-binding sites within the 5Ј-flanking re-gions of the CYP2C9 and CYP2C19 genes that are essential for these responses. In this report, we turn our focus to the most strongly inducible member of the human CYP2C subfamily, CYP2C8. CYP2C8 is the principle enzyme that metabolizes a number of clinically prescribed therapeutics, such as the antidiabetic drugs rosiglitazone and repaglinide, the anticancer drug paclitaxel, the cholesterol-lowering drug cerivastatin, and the antimalarials amodiaquine and chloroquine (Totah and Rettie, 2005) . CYP2C8 is also known to metabolize endogenous molecules, retinoic acid, and arachidonic acid. Because of the significant expression of CYP2C8 in various extrahepatic tissues, this enzyme may play an important role in endogenous signaling. In fact, CYP2C8 and CYP2C9 have been proposed as endothelial-derived hyperpolarizing factor synthetases and are thought to be located in arteries (Fisslthaler et al., 1999) . Therefore, understanding the factors that control CYP2C8 basal expression and induction by drugs is important to understand its biological interactions and better predict adverse drug-drug interactions.
The current consensus is that CYP2C8 Ͼ CYP2C9 Ͼ CYP2C19 is induced by phenobarbital and rifampicin in liver and primary human hepatocytes (Gerbal-Chaloin et al., 2001; Raucy et al., 2002; Madan et al., 2003) . These prototypical inducers are also known to strongly induce CYP2B and CYP3A expression and play significant roles in druginduced drug-drug interactions. Significant progress has been made over the past few years in unraveling the mechanism of these induction processes (Goodwin et al., 1999; Sueyoshi and Negishi, 2001; Wang et al., 2004) . At present, it is thought that both the constitutive androstane receptor (NR1I3) and pregnane X receptor (NR1I2) are important for phenobarbital-mediated drug induction in humans (Wei et al., 2002) .
Rifampicin and other inducers, such as hyperforin (active ingredient in St. John's wort) and paclitaxel, are thought to predominantly activate gene expression by acting as ligands to PXR. Our laboratory, among others, has extended these studies to the CYP2C subfamily. CYP2C9 and CYP2C19 are directly regulated by CAR and PXR (Ferguson et al., 2002; Chen et al., 2003 Chen et al., , 2004 . The clinically prescribed synthetic glucocorticoid dexamethasone has also been shown to induce CYP2C expression (Gerbal-Chaloin et al., 2001) . The glucocorticoid receptor (GR) binds/activates identical GRE halfsites within the 5Ј-flanking regions of the CYP2C9 and CYP2C19 genes and is essential for dexamethasone induction (Gerbal-Chaloin et al., 2002; Chen et al., 2003) . We also have previously identified a site in the 5Ј-flanking region of the CYP2C9 that binds to the nuclear receptor hepatic nuclear factor 4␣ (HNF4␣) and enhances basal promoter activity (Ibeanu and Goldstein, 1995) .
Although CYP2C8 is reported to be the most inducible member of the human CYP2C subfamily, there is a paucity of information concerning the transcription factors and binding sites in the CYP2C8 promoter that control these responses. To explore these regulatory mechanisms, we treated primary human hepatocytes with drugs and isolated RNA for RT-PCR, cloned upstream regions into luciferase reporter vectors and transfected them into cells, and performed gel shift assays to identify nuclear receptor-binding sites. Through these studies, we have identified a distal site for PXR and CAR that is essential for the induction of CYP2C8 reporters in primary human hepatocytes, a putative GR-binding site essential for dexamethasone induction, and a HNF4␣-binding site that is responsive to HNF4␣ cotransfection.
Materials and Methods
Rifampicin, dimethyl sulfoxide, dexamethasone, paclitaxel, CITCO, phenytoin, and lithocholic acid were purchased from SigmaAldrich (St. Louis, MO). Hyperforin was purchased from Chromadex (Laguna Hills, CA). Cell culture media, fetal bovine serum, and trypsin/EDTA were purchased from Invitrogen (Carlsbad, CA). Oligonucleotides were purchased from Sigma-Genosys (The Woodlands, TX) and desalted. Unless specified, all other reagents were obtained from standard sources. All restriction endonucleases and modifying enzymes were purchased from New England Biolabs (Beverly, MA).
Bioinformatics. Regulatory regions of the CYP2C8 gene were obtained via the Celera Discovery System (Applied Biosystems, Foster City, CA) and National Center for Biotechnology Information databases. CAR/PXR-binding sites were identified through customized search motifs and mined using the Discovery Studio GCG (formerly known as GCG Wisconsin Package; Accelrys, San Diego, CA) findpatterns tool as described previously (Ferguson et al., 2002; Chen et al., 2003; Wang et al., 2003; Jackson et al., 2004) . The tfsites.dat database within the Wisconsin package, which contains the Transfac database, was used to identify putative transcription factor-binding sites within the proximal CYP2C8 promoter. All DNAsequencing analyses, vector mapping, and construction and sequence alignments were performed with Vector NTI 9 (InforMax, Bethesda, MD).
Isolation of Total RNA and Quantitative RT-PCR Analysis. Total RNA was extracted using RNeasy mini prep system (QIAGEN, Valencia, CA) following the manufacturer's procedure. RT-PCR analysis was performed in two steps by initial reaction with Superscript II (Invitrogen) reverse transcriptase. PCR with SYBR green PCR Master Mix (Applied Biosystems) was then performed with genespecific primers using standard curves and relative quantitation methods. For the RT reaction, 200 ng of total RNA was combined with 2 l (40 units) of RNase inhibitor (PerkinElmer Life and Analytical Sciences, Boston, MA), 1ϫ First Strand Buffer (final concentration) (Invitrogen), 10 mM dithiothreitol (final concentration), 0.5 mM dATP, dTTP, dGTP, and dCTP (final concentration), and 1 l (200 units) of Superscript II to a total volume of 20 l, incubated at 42°C for 50 min and then inactivated at 70°C for 15 min, and stored at Ϫ20°C or immediately used in PCR analysis. PCR was performed on an Applied Biosystems 7900HT using the standard curves method of relative quantitation. In brief, pooled RT reaction products from 3, 0.3, 0.03, and 0.003 l were run for each target gene and endogenous control gene primer set, and threshold temperatures were determined. Samples were amplified and quantitated via standard curves for each gene. Relative concentrations were normalized for endogenous control gene content, and each sample was calibrated to the vehicle control (DMSO). Using specific primers for CYP2C8 (T570F, 5Ј-AGATCAGAATTTTCTCACCC-3Ј; T730R, 5Ј-AACTTCGTGTAAGA-GCAACA-3Ј), CYP2C9 (65.815F, 5Ј-AGGAAAAGCACAACCAACCA-3Ј; 65.903R, 5Ј-TCTCAGGGTTGTGCTTGTC-3Ј), and ␤-actin (actinF, 5Ј-GAGCTATGAGCTGCCTGACG-3Ј; actinR, 5Ј-CACTTGCGGTGCAC-GATG-3Ј), PCR reactions were run for 45 cycles at annealing temperatures of 50, 53, and 60°C, respectively. Calculations of the mean Ϯ S.E. are shown in the figures, and the p values are indicated by asterisks calculated via ANOVA and Student's t test.
Cloning of CYP2C8 Promoter Sequences and Nuclear Receptors. CYP2C8 5Ј-flanking regions were cloned by PCR amplification of BAC clone DNA RP11-63F3 (Children's Hospital Oakland Research Institute, Oakland, CA). 2C8-2.5kb was amplified with 2C8-2527F-NheI_F (5Ј-GCTAGCAATGCTAATACACTCTTGATC-3Ј) and 2C8-1bpHindIII_R (5Ј-AAGCTTTGAAGCCTTCTCTTCTTAT-TAAG-3Ј), subcloned into pCR2.1 vector, sequenced via Big Dye Terminator Cycle sequencing method (Applied Biosystems), and cloned into pGL3-Basic luciferase reporter vector (Promega, Madi-son, WI) via NheI and HindIII restriction sites. 2C8-3kb luciferase reporter construct was prepared by amplification of BAC clone DNA with primers 2C8-2966bpMluI_F (5Ј-ACGCGTAACACTAAAGT-GAACTGTGG-3Ј) and 2C8-2461bp_R (5Ј-AATCCCAGTTTTCCT-GCTTGGTG-3Ј), subcloning into pCR2.1, sequencing, and final cloning via MluI and an endogenous EcoRI site within the 2C8-2.5kb luciferase reporter described above. 2C9-3kb#1 was constructed and described previously (Chen et al., 2004) . 2C8-(Ϫ8.9 to Ϫ8.5)-TK-Luc was constructed by amplification of a 417-bp region flanking the putative CAR/PXR-binding site located at Ϫ8806 bp from the translation start site with 2C8-8888SacI-F (5Ј-GAGCTCTAGCCATACTA-ATATCAGAC-3Ј) and 2C8-8471PacIR (5Ј-TTAATTAATAGAAACAT-TGTCTCAGTATGT-3Ј) primers, subcloning, and subsequent digestion with SacI to insert upstream of the pGL3-TK reporter construct (Promega). This region was subsequently inserted upstream of the 2C8-2.5kb and 2C8-3kb constructs to make 2C8-(Ϫ8.9 to Ϫ8.5)-2.5kb and 2C8-(Ϫ8.9 to Ϫ8.5)-3kb, respectively, at the SacI sites of each vector. Construction of 2C8-300bp was analogous to 2C8-2.5kb but using 2C8-301bpNheI_F primer (5Ј-GCTAGCAGT-GTTTCTCCATCATC-3Ј). Mutation of the putative CAR/PXR-binding site at Ϫ8806 was performed via the QuikChange method (Stratagene, La Jolla, CA) using primers Qchange2C8-8806F (5Ј-GAAGAAACAAATAAGTCAAGGTTGAGGACCCCATTTAATGA-TAAT-3Ј) and Qchange2C8-8806R (5Ј-ATTATCATTAAATGGGGTC-CTCAACCTTGACTTATTTGTTTCTTC-3Ј); bold letters indicate mutated nucleotides. Analogous mutations were performed to make 2C8-(Ϫ8.9 to Ϫ8.5)-3kbmut8806 that were verified by DNA sequencing. Mutation of the putative CAR/PXR-binding site at Ϫ2796 bp was generated with Qchange2C8-2796_F (5Ј-CAAACAGTAAACCCTAT-GGACACTTCGAACTTTGGTTG-3Ј) and Qchange2C8-2796_R (5Ј-CAACCAAAGTTCGAAGTGTCCATAGGGTTTACTGTTTG-3Ј) primers to make 2C8-(Ϫ8.9 to Ϫ8.5)-3kbmut2796 and 2C8-(Ϫ8.9 to Ϫ8.5)-3kbdoublemut, which was verified by DNA sequencing. Mutation of the putative GRE at Ϫ1927 bp of the CYP2C8 promoter was performed via the QuikChange method using primers Qchange2C8-GREmut_F (5Ј-CAATCTTGGTGGCCCGGTTTCCCTGGATGTTTT-GCTTAAAAGG-3Ј) and Qchange2C8-GREmut_R (5Ј-CCTTTTAAG-CAAAACATCCAGGGAAACCGGGCCACCAAGATTG-3Ј) to make 2C8-2.5kb-GREmut. Mutation of the putative HNF4␣-binding site at Ϫ154 bp was accomplished by amplifying with mutant PCR primers 2C8-mutPCR-HNF4␣-NcoI-154bp_F (5Ј-CCATGGGCGTTTCACC-ACTCAGAAAAAAAGTAT-3Ј) and 2C8-1bpHindIII_R and subcloning and cloning this insert to make 2C8-300bpmutHNF4#5 and 2C8-2.5kbmutHNF4␣. Mammalian expression vectors pCR3.0-h-CAR, pCR3.1-GR, and pSG5-hPXR(atg) were described previously (Ferguson et al., 2002; Chen et al., 2003) . pCR3.0-HNF4␣ was constructed by amplification of cDNA with gene-specific primers (forward primer, 5Ј-CTCGTCGACATGGACATGGCCGACTAC-3Ј; reverse primer, 5Ј-GGCTTGCTAGATAACTTCCTGCTTGGT-3Ј) and subcloned into pCR2.1 for sequence verification. This insert was then cloned into pCR3.0 via HindIII and XbaI enzymes, and DNA sequencing confirmed the final mammalian HNF4␣ expression vector.
Cell Culture and Transfections. HepG2 and HeLa cells (obtained from American Type Culture Collection, Manassas, VA) were cultured in Eagle's minimal essential medium with 31 mg/liter penicillin and 50 mg/liter streptomycin and supplemented with 10% fetal bovine serum. Primary human hepatocytes were purchased from CellzDirect (Pittsboro, NC). Primary hepatocytes were maintained in William's E Medium with 31 mg/liter penicillin and 50 mg/liter streptomycin without phenol red and supplemented with ITS (BD Biosciences, San Jose, CA) on collagen-coated plates (Biocoat, Fort Washington, PA). Transfections were performed with Effectene transfection reagent (QIAGEN) using procedures stipulated by the manufacturers, and conditions were optimized for either HepG2/HeLa cells or primary human hepatocytes. All cells for transfection experiments were plated in a 24-well format and transfected for 12 to 18 h, and fresh medium was applied before drug treatments. All transfected plasmids were prepared via QIAGEN Maxi-prep methods, quantitated, and diluted to 100 ng/l before transfection. Cells were subsequently lysed with 100 l of passive lysis buffer (Promega) for 0.5 h at room temperature with gentle rocking. Dual Luciferase Assays (Promega) were then performed on cell lysates based on the procedures stipulated by the manufacturer.
Gel Mobility Shift Assays. Electrophoretic mobility shift assays were performed as described previously (Ferguson et al., 2002) . In brief, human HNF4␣, human RXR, human CAR, and human PXR were synthesized in vitro using the TNT Quick Coupled in vitro transcription/translation system (Promega) following the manufacturer's protocol. Probes were labeled with [␥-32 P]dCTP purified by Microspin G-25 columns (Amersham Biosciences Inc., Piscataway, NJ). Labeled probe (150,000 cpm) was applied to each binding reaction in 10 mM HEPES, pH 7.6, 0.5 mM dithiothreitol, 15% glycerol, 0.05% Nonidet P-40, 50 mM NaCl, 1 g of poly(dI-dC), and 1 to 2 l of in vitro transcribed/translated proteins to a final reaction volume of 10 l. The reactions were incubated at room temperature for 20 min and then loaded on 5% acrylamide gels in Tris-buffered EDTA, dried, and exposed to film for 6 to 18 h at Ϫ70°C. Wild type and mutant nonradioactive competitors were generated by denaturing and annealing unlabeled primers and applied to binding reactions at the indicated concentrations. Antibodies to RXR␣ and HNF4␣ were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).
Statistical Analyses. All error bars indicate the mean Ϯ S.E. The p values for each experimental comparison were determined using the ANOVA and Student's t test. For comparison, all of the p values were determined relative to the vehicle or untreated controls.
Results

CYP2C8 Induction in Primary Human Hepatocytes.
To confirm that CYP2C8 mRNA was induced by drugs in our hands, we first treated primary human hepatocytes with 10 M rifampicin and 500 M phenobarbital for 48 h, isolated RNA, and performed quantitative RT-PCR with gene-specific primers (Fig. 1A) . We observed an 8-fold induction of CYP2C8 mRNA by rifampicin and a more modest 2-fold activation (p ϭ 0.15) by phenobarbital in hepatocytes from this donor. CYP2C9 was also induced 3-fold by rifampicin (p Ͻ 0.001); however, a modest induction by phenobarbital was not statistically significant. In Fig. 1B , an analogous experiment was performed using rifampicin and 10 M paclitaxel, which is a potent anticancer drug and substrate for CYP2C8 and a ligand for PXR. In this donor, both rifampicin and paclitaxel induced CYP2C8 expression, consistent with previous reports in primary human hepatocytes (GerbalChaloin et al., 2001; Raucy et al., 2002) . Figure 1C contains quantitative RT-PCR data from CYP2C8 mRNA in a third set of primary human hepatocytes treated with various inducers for 24 h. Herein, PXR-type ligands such as rifampicin produced a 4-fold induction of CYP2C8 expression. Hyperforin (active component of the antidepressant herbal remedy St. John's wort) has been shown to mediate the induction of CYP3A4 and CYP2C9 via the nuclear receptor PXR (Moore et al., 2000; Chen et al., 2004) . Herein, we show that treatment of primary human hepatocytes with 400 nM hyperforin for 24 h induces CYP2C8 mRNA accumulation 5-fold relative to DMSO-control samples and comparable with the 4.4-fold induction observed with rifampicin. Another reported PXR ligand, lithocholic acid, produced a marginal but statistically significant induction of CYP2C8 mRNA at a concentration of 50 M. In addition to prototypical PXR ligands, we also examined induction by two reported CAR agonists, phenytoin and, the recently reported human CAR-specific ligand, CITCO (Maglich et al., 2003) . Both phenytoin and CITCO induced CYP2C8 expression in hepatocytes from this patient, indicating that CAR may also regulate CYP2C8. Treatment with 10 M dexamethasone weakly (Ͻ2-fold) increased CYP2C8 expression in primary human hepatocytes under the experimental conditions used. From these data, we confirm the reports of others that rifampicin, phenobarbital, and paclitaxel can induce CYP2C8 expression in primary human hepatocytes. In addition, we show for the first time that human CAR-type agonists, phenytoin and CITCO, induce CYP2C8 expression, whereas the herbal ingredient, hyperforin, strongly induces CYP2C8 mRNA accumulation similar to rifampicin.
What Factors May Regulate CYP2C8 Expression? To explore the mechanisms of induction, we examined the 5Ј-flanking region of the CYP2C8 gene. We identified a number of putative transcription factor-binding sites within the CYP2C8 proximal 2000-bp 5Ј-flanking sequence. CYP2C8 contains several TATA boxes in this segment. Ged and Beaune (1991) identified 2477 bp of 5Ј-flanking sequence, suggested several putative glucocorticoid receptor-response elements, and reported that the transcription start site for CYP2C8 resides at Ϫ23 bp relative to the translation start site. This observation is consistent with initiation at the most proximal TATA box at Ϫ56 to Ϫ51 bp. However, a CYP2C8 cDNA sequence from human liver deposited in GenBank TM (accession number BC020596) contains 95 bp of the 5Ј-flanking sequence that is consistent with transcription initiation from the more distal TATA box at Ϫ126 to Ϫ121 bp (Strausberg et al., 2002) . Thus, it is possible that both TATA boxes are functional in liver. We also observed a putative HNF4␣-binding site at Ϫ154 bp that has previously been observed (Cairns et al., 1996) ; however, this site has not been characterized to date. Putative sites for HNF5 (Ϫ1130 and Ϫ1352 bp), HNF6 (Ϫ1508 and Ϫ1945 bp), and HNF3 (Ϫ1042, Ϫ1132, and 1341 bp) were also found along with more general transcription factor sites, such as the GATA-binding protein (multiple sites) and two CCAAT enhancer-binding protein sites [Ϫ1007 bp, previously noted by Klose et al. (1999) , and an additional site at Ϫ185 bp]. All of these sites are upstream of the transcription start site and may function as enhancers or in the basal transcription machinery. HNF3 has recently been shown to activate transcription of all of the CYP2C promoters (Bort et al., 2004) . It is noteworthy that we observed that a site at Ϫ2056 bp in CYP2C8 was homologous to a CAR-RE site identified for CYP2C9 at Ϫ1836 bp (GerbalChaloin et al., 2002; Chen et al., 2004) . However, the site in CYP2C8 did not match our previously described consensus CAR/PXR-binding site search motif (Ferguson et al., 2002) . We also found that CYP2C8 contained a putative glucocorticoid receptor-response element at Ϫ1927 bp that is homologous to the GRE identified for CYP2C9.
CYP2C8 Induction Mechanism Distinct from CYP2C9 and CYP2C19. Because of the inducibility of CYP2C8 by rifampicin and phenobarbital and the clear evidence for PXR and CAR in the regulation of CYP2C9 via a proximal CAR-RE, we first tested whether the homologous element within the CYP2C8 5Ј-flanking region may be responsible for the rifampicin induction through PXR. Thus, we examined the ability of CAR/PXR to bind to these homologous elements in gel-shift assays. Figure 2 shows that in vitro transcribed/translated CAR and PXR, in the presence of the RXR, binds strongly to the CAR-RE at Ϫ1836 bp of the CYP2C9-positive control, whereas the homologous CYP2C8 element at Ϫ2056 bp does not significantly bind to either CAR or PXR proteins in the same experiment. These data indicate that this site is not capable of binding CAR/PXR and is probably not responsible for CAR/PXR-mediated drug induction of CYP2C8.
We further tested whether elements located in the proximal 3 kb of the CYP2C8 5Ј-flanking region could be activated by CAR or mediate rifampicin induction via PXR in gene reporter assays. Luciferase reporter constructs for CYP2C9 and CYP2C8 were transfected into HepG2 cells and cotransfected with mammalian expression vectors for human CAR or PXR. Figure 3 shows that whereas CYP2C9-3kb reporter constructs were significantly activated by human CAR and induced by rifampicin in the presence of human PXR in HepG2 cells, the CYP2C8-3kb reporter construct was not activated by either receptor. These data are consistent with the lack of CAR/PXR binding to the CYP2C8 element at Ϫ2056 bp.
Identification of a Putative Far-Upstream CAR/PXRBinding Site within the CYP2C8 Promoter. Because of the absence of CAR/PXR activation within the proximal 3 kb of the CYP2C8 promoter and the clear induction of CYP2C8 by CAR/PXR agonists, we obtained genomic DNA sequence from the Celera Discovery database and searched for CAR/ PXR-binding sites further upstream using the Findpatterns tool in the GCG software suite. In the case of CYP3A4, a DR-3 element at Ϫ7733 bp was shown to play a major role in PXR-mediated drug induction. We discovered that CYP2C8 contains a perfect match to our consensus DR-4 CAR/PXRbinding sequence in the far upstream of the CYP2C8 promoter at Ϫ8806 bp (Fig. 4) . This element is nearly identical to the CYP3A4 element at Ϫ7733 bp and similar to the CYP2C9 CAR-RE element at Ϫ1839 bp. Moreover, this element bound CAR and PXR in gel-shift assays (Fig. 4) . From this representative assay, it is clear that both CAR and PXR in the presence of RXR are able to bind both oligonucleotides from the CYP2C9 element (positive control) and the newly discovered CYP2C8 element located at Ϫ8806 bp. These binding interactions were specifically decreased by competition with 20ϫ nonradioactive competitor double-stranded oligonucleotides.
In addition to the CAR-binding site at Ϫ8806 bp, we also identified a putative DR-5 element at Ϫ2796 bp (Fig. 5) . This site is homologous with the DR-5 identified in the CYP2C9 promoter but differs by two nucleotides from CYP2C9, making the CYP2C8 sequence a better match to our consensus CAR/PXR-binding sites. Consistent with this observation, CAR/RXR efficiently bound this CYP2C8 element in gel-shift assays, 10ϫ nonradioactive competitor (Fig. 5 ) decreased the Fig. 2 . Gel-shift assay with 2C9-proximal CAR-RE and homologous 2C8 sequence. Electrophoretic mobility shift assays were performed with oligonucleotide probes labeled with 32 P, and binding reactions were performed with in vitro transcribed/translated CAR/RXR or PXR/RXR proteins. Top, comparison of homologous elements from CYP2C8 and CYP2C9 with two mismatches in their half-sites. Left, positive control CYP2C9 sequence known to bind and be activated by CAR and PXR/ rifampicin. Right, homologous sequence for CYP2C8, indicating that neither CAR and PXR nor their heterodimers with RXR are able to bind the putative CAR-RE CYP2C8 element at Ϫ2056 bp. Competition for binding was done with 20ϫ nonradioactive competitor oligonucleotides to show probe specificity. These data indicate that the element homologous to the principle element responsible for CYP2C9 induction is not capable of efficiently binding CAR or PXR in the CYP2C8 promoter. 
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at ASPET Journals on July 21, 2017 molpharm.aspetjournals.org intensity of this complex, whereas 100ϫ nonradioactive competitor essentially eliminated the band (data not shown). Treatments with anti-RXR antibodies demonstrated a clear supershifted band. Although the apparent expression/binding of PXR with RXR to the positive control was much lower in this particular experiment than that of CAR/RXR, PXR/ RXR bound equally well to our positive control element and the Ϫ2796-bp element, demonstrating that this element can bind both CAR and PXR. However, because of the absence of activation/induction of the 2C8-3kb luciferase reporter as shown in Fig. 3 , the possible role of this binding site in CYP2C8 regulation by CAR and PXR remains unclear.
Rifampicin Induction for CYP2C8 Is Observed in Primary Human Hepatocytes But Not HepG2 Cells. Subsequent to the identification of the CAR/PXR-binding site at Ϫ8806 and positive gel shift data for both CAR and PXR, we cloned a 400-bp region flanking this sequence and inserted it upstream of the CYP2C8-2.5kb reporter construct. The proximal CYP2C8-2.5kb reporter is not responsive to CAR/PXR in either HepG2 cells (data not shown) or primary human hepatocytes (Fig. 6B ). This new construct [2C8-(Ϫ8.9 to Ϫ8.5)-2.5kb] was transfected into HepG2 cells along with CAR and PXR expression plasmids. We were surprised to observe that although the CYP2C9 control reporters were activated by both CAR and PXR-rifampicin, no rifampicin induction was observed with the 2C8-(Ϫ8.9 to Ϫ8.5)-2.5kb construct in HepG2 cells (Fig. 6A) . A modest 2.5-fold activation was observed with this reporter by the addition of CAR expression plasmids, but this was much lower than that observed for the CYP2C9-positive control.
Because CYP2C8 is induced in primary human hepatocytes by phenobarbital, rifampicin, and other CAR/PXR activators, we transfected fresh primary human hepatocytes with this CYP2C8 reporter construct and control reporters in the presence of either 0.2% DMSO vehicle or 10 M rifampicin (Fig. 6B) . These data show that, whereas the CYP2C8-2.5kb construct remains nonresponsive to rifampicin treatment, insertion of the 400-bp distal region within 2C8-(Ϫ8.9 to Ϫ8.5)-2.5kb confers rifampicin inducibility to the CYP2C8 reporter in primary hepatocytes. These data indicate that HepG2 cells may be insufficient to support CYP2C8 induction via CAR/PXR. However, in primary human hepatocytes, which constitute the best current model system for human liver, we observed both induction of endogenous mRNA by rifampicin and increased transcription with CYP2C8 reporter constructs containing the distal element.
Induction within a Heterologous Thymidine Kinase Reporter Shows That the Element at ؊8806 bp Is Essential for Rifampicin Induction. To further test the inducibility of this distal region of the CYP2C8 promoter, it was cloned upstream of the heterologous thymidine kinase promoter to make 2C8-(Ϫ8.9 to Ϫ8.5)-TK. We transfected this construct into both HepG2 cells (no response to CAR/PXR analogous to the lack of response observed upstream of the 2C8-2.5kb reporter, data not shown) and primary human hepatocytes (Fig. 7) . Rifampicin induced transcription of this construct in primary human hepatocytes in a manner similar to the induction seen when the distal region was present upstream of the natural CYP2C8 promoter (Fig. 6B) . Furthermore, mutation of the CAR/PXR-binding site at Ϫ8806 bp abolished this induction, indicating that this DR-4 ele- 5 . Gel shift assay with CYP2C8 proximal DR-5 element at Ϫ2796 that does bind CAR and PXR heterodimers with RXR␣. Electrophoretic mobility shift assays were performed with oligonucleotide probes labeled with 32 P and bound with in vitro transcribed/translated CAR/RXR or PXR/RXR proteins and supershifted with anti-RXR␣ antibodies. Top, comparison of these homologous elements from CYP2C8, CYP2C9, and CYP2C19 (the homologous element from CYP2C19 does not bind CAR/ RXR or PXR/RXR), with boxes indicating sequence differences. This representative gel image shown below contains our positive control CYP2C8 element at Ϫ8806 (left) that typically binds both CAR/RXR and PXR/RXR with equal affinity (in this gel, the PXR/RXR binding to this control was significantly weaker than CAR/RXR but clearly observable). 10ϫ Nonradioactive competitor (cc) was applied in this experiment; however, higher concentrations have been used in other experiments that completely abolish this interaction (data not shown). The DR-5 element at Ϫ2796 seems to bind both CAR/RXR and to a PXR/RXR but slightly weaker than the positive control. Anti-RXR␣ antibodies (Santa Cruz Biotechnology) were used to supershift complexes and show that RXR␣ is present in the shifted complexes for both CAR and PXR heterodimers. 
Both CAR and PXR Agonists Induce CYP2C8 Reporter Constructs in Primary Hepatocytes. To further address the CYP2C8 induction mechanism in primary human hepatocytes, we transfected various CYP2C8 promoter reporter constructs into primary cells and treated them with 0.2% DMSO, 10 M rifampicin, or 400 nM CITCO (Fig. 8) .
For the first time, we showed that a human CAR agonist (CITCO) is effective in activating a CYP2C9 reporter constructs (3.7-fold). A 5-fold induction response was seen with the PXR agonist rifampicin. No induction was observed for CYP2C8 reporter constructs containing the proximal Ϫ3 kb alone or mutant of a putative CAR/PXR-binding site at Ϫ2796 bp. Consistent with previous experiments, 2C8-(Ϫ8.9 to Ϫ8.5)-3kb was activated by rifampicin (3.5-fold), whereas the hCAR-specific agonist, CITCO, induced CYP2C8 reporter constructs to an even greater extent (5.3-fold). These data demonstrate that both CAR-and PXR-specific agonists regulate CYP2C8 transcription in primary human hepatocytes. Mutation of the CAR/PXR-binding site at Ϫ8806 bp [2C8-(Ϫ8.9 to Ϫ8.5)-3kbmut8806] completely abolished the induction response from both rifampicin and CITCO. Thus, this single element seems to be essential for the PXR-mediated and the CAR-mediated induction of CYP2C8 in primary hepatocytes. Mutation of the putative proximal element at Ϫ2796 alone had no effect on rifampicin or CITCO activation of the 2C8-(Ϫ8.9 to Ϫ8.5)-3kb reporter construct, whereas mutation of both the Ϫ8806 distal and Ϫ2796 proximal elements (doublemut) abolished the drug induction responses. In total, these data demonstrate that the CAR/PXR-binding site at Ϫ8806 bp is required for both rifampicin and CITCO induction and that no additional responsive elements in the proximal Ϫ3 kb of the CYP2C8 promoter seem to contribute to the CAR or PXR-mediated induction of CYP2C8.
Dexamethasone Induction of CYP2C8 Is Regulated via a Glucocorticoid-Responsive Element. Maurel and co-workers have demonstrated that dexamethasone induced CYP2C8 mRNA accumulation in primary human hepatocytes (Gerbal-Chaloin et al., 2001) . In the present study, we identified a putative GRE at Ϫ1927 bp in the CYP2C8 pro- Fig. 7 . Primary human hepatocytes support CYP2C8 induction via the far upstream region with a heterologous thymidine kinase promoter. Luciferase constructs containing the 400-bp region, including the CAR/ PXR-binding site at Ϫ8806 bp and mutant construct at the Ϫ8806-bp element (mutant generated indicated at the top) upstream of the thymidine kinase promoter, along with control plasmids were transfected into primary human hepatocytes. Two hundred nanograms of each construct with 20 ng of the pRL-TK internal transfection control plasmid were also transfected. Rifampicin concentrations were 10 M, whereas all of the samples contained 0.2% DMSO for 24 h after transfection. Error bars indicate mean Ϯ S.E. calculations of a minimum of three independent samples. ‫,ء‬ p Ͻ 0.05 relative to the DMSO vehicle controls. WT, wild type; Mut, mutant. Fig. 6 . Primary human hepatocytes support CYP2C8 induction via the far upstream region. The proximal 2500 bp of CYP2C8 and 3000 bp of CYP2C9 5Ј-flanking sequences were cloned upstream of the luciferase gene within the promoterless pGL3-Basic vector. The far upstream region of CYP2C8 from Ϫ8.9 to 8.5kb was inserted upstream of CYP2C8 -2.5kb to make 2C8(Ϫ8.9 to Ϫ8.5)-2.5kb. These reporters were transfected into HepG2 (A) or primary human hepatocytes (B). In HepG2 cells, 100 ng of luciferase reporter and hPXR, empty pCR3.1, and hCAR mammalian expression plasmids were cotransfected at 100 ng each with 10 ng of the pRL-TK internal transfection control plasmid. 200 ng of luciferase reporters were transfected into primary human hepatocytes. Rifampicin (Rif) concentrations were 10 M, whereas all of the samples contained 0.2% DMSO. Error bars indicate mean Ϯ S.E. of a minimum of three independent samples. *, p Ͻ 0.05; **, p Ͻ 0.01, ‫,ءءء‬ p Ͻ 0.001 relative to the pCR3.1 empty vector control.
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at ASPET Journals on July 21, 2017 molpharm.aspetjournals.org moter that is homologous with the GREs identified in the CYP2C9 (Gerbal-Chaloin et al., 2002) and CYP2C19 (Chen et al., 2003) genes (Fig. 9) . In both HepG2 and HeLa cells transfected with GR mammalian expression plasmid, the synthetic glucocorticoid dexamethasone induced CYP2C8 reporter constructs. Mutation of the putative GRE-binding site (GRE-mut) resulted in a complete loss of dexamethasone induction, indicating that this is the essential site for induction of CYP2C8 by glucocorticoids. In total, these data indicate that, unlike CAR and PXR agonists, dexamethasone, a GR-specific ligand, is capable of inducing CYP2C8 gene reporter constructs in HepG2 cells and the response in HeLa cells may suggest that glucocorticoids might also regulate CYP2C8 expression in extrahepatic tissues.
HNF4␣ Regulation of CYP2C8 via Proximal Binding Site. CYP2Cs have previously been shown to be regulated by HNF4␣; however, no studies have been reported on demonstrating its involvement in the regulation of CYP2C8. We cloned the coding region of human HNF4␣ into a mammalian expression vector to study its role in CYP2C regulation. Figure  10A shows a gel-shift assay with oligonucleotides from a putative HNF4-binding site at Ϫ154 bp from the translation start site that is homologous with an HNF4 site identified previously for CYP2C9 (Ibeanu and Goldstein, 1995) . These data show that this site is capable of strongly binding to in vitro transcribed/translated HNF4␣. This binding interaction is specifically inhibited by wild-type cold competitor but is not inhibited by mutant cold competitor. In addition, anti-HNF4␣ antibodies were capable of supershifting the HNF4␣ complex.
We next transfected HeLa cells and HepG2 cells with a CYP2C8 luciferase reporter construct in the presence/absence of HNF4␣. Although exogenous HNF4␣ did not seem to activate the CYP2C8 promoter in HepG2 cells, this promoter was strongly activated by HNF4␣ (29-fold) in HeLa cells (Fig.  10B) . HNF4␣ activation was greatly attenuated (85% decrease) by mutation of the element at Ϫ154 bp of the CYP2C8 promoter. Because the empty pGL3-Basic control vector was activated slightly by HNF4␣ in these assays, the observed 85% attenuation could be adjusted to ϳ93% by accounting for this nonspecific activation of the luciferase vector backbone. Thus, the element at Ϫ154 bp of the CYP2C8 promoter seems to account for the majority of HNF4␣-mediated activation within this 300-bp region. Fig. 8 . The far upstream CAR/PXR-binding site is essential for rifampicin and CITCO induction for CYP2C8 reporter constructs in human hepatocytes. Luciferase constructs containing the proximal 3000 bp of the CYP2C8 promoter or both proximal element and far upstream 400-bp region containing the CAR/PXR-binding site at Ϫ8806 bp along with control plasmids were transfected into primary human hepatocytes. Each construct (200 ng) with 20 ng of the pRL-TK internal transfection control plasmid was transfected using the Effectene method (QIAGEN). Drug treatments with 10 M rifampicin and 400 nM CITCO were performed for 24 h and compared with vehicle (0.2% DMSO) controls. Error bars indicate mean Ϯ S.E. calculations of a minimum of three independent samples. ‫,ء‬ p Ͻ 0.05; ‫ءء‬ p Ͻ 0.01; and ‫,ءءء‬ p Ͻ 0.001 relative to respective DMSO vehicle controls. Fig. 9 . The glucocorticoid receptor mediates dexamethasone (Dex) induction of CYP2C8 via an essential DR-3 element in the proximal promoter region. Luciferase reporter constructs for CYP2C8 containing 2.5 kb of the proximal promoter and CYP2C9 control reporters were transfected into HepG2 (A) and HeLa (B) cells along with our mutant GRE reporter in the presence of GR mammalian expression vectors or empty vector control (pCR3.1). Top left, the GRE sites from CYP2C8 and CYP2C9 along with our mutated CYP2C8 element (GREmut). Luciferase reporters (100 ng) and human GR were transfected along with 10 ng of pRL-TK internal control plasmid. Cells were transfected for 16 h and then treated with either 10 M dexamethasone or 0.2% DMSO vehicle and incubated for another 36 h before cell lysis. Error bars indicate mean Ϯ S.E. calculations of a minimum of three independent samples. ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 relative to respective DMSO vehicle controls.
Discussion
In the present study, we have demonstrated functional roles for the nuclear receptors CAR, PXR, GR, and HNF4␣ in the transcriptional regulation of CYP2C8 expression and identified specific regulatory elements within the 5Ј-flanking region that are essential for these cell-signaling pathways. A CAR/PXR-binding site was identified at Ϫ8806 bp (DR-4) that is essential for the activation of the CYP2C8 promoter by both the PXR ligand rifampicin and the human CAR ligand, CITCO (Maglich et al., 2003) , in primary human hepatocytes. In addition, along with rifampicin and CITCO, other CAR/ PXR agonists such as phenobarbital, phenytoin, hyperforin, and paclitaxel were also shown to induce CYP2C8 mRNA, further supporting a role for these receptors in the regulation of CYP2C8 expression by drugs. The glucocorticoid receptor was shown to mediate dexamethasone induction of CYP2C8 reporter expression in both HepG2 and HeLa cells, and mutation of a single putative GR-binding site (DR-4) at Ϫ1927 bp resulted in a complete loss of dexamethasone induction. Finally, HNF4␣ was shown to bind to the CYP2C8 promoter at a DR-1 element in the proximal promoter region (Ϫ154 bp), and mutation of this element resulted in a marked decrease in the constitutive activation by HNF␣ of CYP2C8 reporter activity in HeLa cells.
Examination of the CYP2C8 basal promoter region revealed several putative binding sites that may be involved in CYP2C8 transcription: TATA-binding protein (TATA) (two sites as previously reported), HNF3, CCAAT enhancer-binding protein, HNF4␣, and GATA-binding protein. HNF3, a member of the FOXO family of transcription factors, has recently been shown to regulate CYP2C expression in cell lines (Bort et al., 2004) . Thus, many potential nuclear factors may be involved in controlling CYP2C8 transcription in liver and extrahepatic tissues and influence endogenous CYP2C8-mediated cellular metabolism. In the present study, we have shown that CYP2C8 transcription can be regulated by several nuclear receptors and that future studies with some of these other factors may elucidate a more complete understanding of the signal transduction pathways that control CYP2C8 expression.
Preliminary examination revealed that CYP2C8 contains putative sites in the proximal 3-kb promoter that are homologous to those shown to be essential for the regulation of CYP2C9 by CAR and PXR agonists (Fig. 11 ). We were surprised to observe that, although CAR and PXR agonists induced CYP2C8 mRNA, the proximal 3-kb region of CYP2C8 did not seem to be transcriptionally regulated by drugs in either HepG2 cells transfected with PXR or in primary human hepatocytes. Close inspection of the proximal elements from CYP2C8 and CYP2C9 and gel shift assays of these elements with CAR and PXR proteins revealed that two base differences between the CYP2C9 and CYP2C8 elements prevented CAR/PXR from binding to the proximal element from CYP2C8 at Ϫ2056 bp. The location and identity of the more distal half-site within this element seem to be critical for CAR/PXR binding. A more distal DR-5 element at Ϫ2796 bp does bind CAR and PXR; however, it does not seem to participate in the transcriptional activation of the CYP2C8 promoter in our experiments. Thus, no CAR/PXR-responsive elements could be identified within the proximal 3000 bp of the CYP2C8 promoter, which is unique for the CYP2C promoters. It is possible that other sites are present between our Fig. 10 . Identification of a functional HNF4␣-binding site in the basal promoter region of the CYP2C8 promoter. A, gel shift assays were performed on a putative HNF4␣/HPF-1 binding site at Ϫ154 bp of the CYP2C8 promoter with in vitro transcribed/translated HNF4␣. Wild-type and mutant nonradioactive competitors were used to show specificity of probe/protein binding, and anti-HNF4␣ antibody (Santa Cruz Biotechnology) was used to verify HNF4␣ presence in the complex. B, sequence comparison of the CYP2C8 and CYP2C9 promoters shows two differences between the HNF4␣ binding site of CYP2C9 and the putative site identified in CYP2C8. We mutated this element and transfected HeLa cells with 100 ng of luciferase reporter constructs containing 300 bp of CYP2C8 5Ј-flanking sequence along with control plasmids using 10 ng of the pRL-TK internal control plasmid. Error bars indicate the mean Ϯ S.E. calculations of a minimum of three independent samples. ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001 relative to respective DMSO vehicle controls. Fig. 11 . Summary figure comparing known response elements for CAR, PXR, GR, and HNF4␣ for the CYP2C8 and CYP2C9 genes. This figure summarizes our current view of the regulatory elements within the CYP2C8 and CYP2C9 promoters. The X indicates that although the element is homologous between these genes, this site in CYP2C8 does not bind to CAR/PXR; the boldface question mark indicates that although a second element in CYP2C8 seems to bind CAR/PXR, it is not essential for the induction response to CAR and PXR agonists. All of the other elements shown on the promoter seem to be essential to the efficacy of receptor activation of gene reporters. 
Regulation of the Human
